Lorlatinib in ALK-Rearranged Lung Cancer

Cancer Cell. 2021 Jan 11;39(1):25-27. doi: 10.1016/j.ccell.2020.12.017.

Abstract

Should lorlatinib be the standard first-line treatment in advanced ALK-rearranged lung cancer? In the New England Journal of Medicine, Shaw et al. present interim analysis results from CROWN, a randomized, phase 3 study comparing lorlatinib with crizotinib as initial therapy in patients with advanced ALK-rearranged NSCLC.